Biodegradable implants with stenting capacity, now may regenerate vascular tissue within arteries, as shown in a proof-of-concept study conducted by STENTiT and the Eindhoven University of Technology. These implants hold the potential to restore affected arteries in a minimally invasive way, by exploiting the natural healing response of the body. The results are now published in the prestigious JACC: Basic to Translational Science.
The renowned Journal of the American College of Cardiology (JACC) published in their specialist journal Basic to Translation Science, the promising proof-of-concept results on STENTiT’s bioresorbable endovascular support grafts.
In a short-term proof-of-concept study, which was conducted in close collaboration with the Eindhoven University of Technology, the fully biodegradable fibrillated implants of STENTiT where positioned using a transcatheter approach in a small animal model. After 2 months, the implants have shown the capacity to rebuild native-like vascular tissue components inside the existing artery, while the device gradually degraded over time. One of the most striking findings was the formation of endoluminal elastin, which tissue component is believed to play an important role in the protection from vascular diseases.
The intention behind the STENTiT technology, is to ultimately treat patients suffering from cardiovascular diseases and provide them with a biodegradable implant that can regenerate their affected arteries in a fully minimally-invasive way.
The paper “Transcatheter-Delivered Expandable Bioresorbable Polymeric Graft With Stenting Capacity Induces Vascular Regeneration” was published on 23rd of November 2020 in JACC: Basic to Translational Science. DOI: 10.1016/j.jacbts.2020.09.005